MED12 and sarcoma: Although MED12 is not useful as a prognostic factor or a potential marker for FAs or PTs, in accordance with previous findings, MED12 exon 2 mutation, when detected, could help distinguish PTs from other spindle neoplasms of the breast, such as myofibroblastomas, nodular fasciitis, and sarcomas, which is also a common scenario in breast pathology when it faces a stromal lesion20.